Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer

Published:2017-09 Issue: Volume:111 Page:43-50
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Shen Lan,Niu Xiaomin,Jian Hong,Xu Yunhua,Yu Yongfeng,Lu Shun

Funder

National Natural Science Foundation of China (NSFC)

Project of Shanghai Municipality Science & Technology Commission

Youth Foundation of Shanghai Municipal Public Health Bureau

Science and Technology Innovation Fund of Shanghai Jiao Tong University

of Shanghai Jiao Tong University

“Shanghai Young Physician Development Program” of Shanghai Municipal Public Health Bureau

the“1050 Talents Project” of Shanghai Chest Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Global cancerstatistics, 2012;Torre;CA Cancer J. Clin.,2015

2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J. Clin. Oncol.,2008

3. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study;Ciuleanu;Lancet,2009

4. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

5. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer;Paz-Ares;J. Clin. Oncol.,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergy Mechanisms of Rhizoma Paridis Saponins on Non-small Cell Lung Cancer: Segmented Solid Phase Extraction, Bioactivity Screening, and Network Pharmacology;Anti-Cancer Agents in Medicinal Chemistry;2022-12

2. Maintenance Therapy in Metastatic Solid Tumors;American Journal of Clinical Oncology;2019-08